GSK chief given time to restore growth

Shareholders warn that growth must ‘revive by next year’

Suffering Australian miners turn to pot

Resources groups swap mechanical diggers for medicinal marijuana

Small-cap Week, May 23

Tungsten, Zytronic, Quantum Pharma and Mar City featured

Hikma founder Samih Darwazah dies at 85

Palestinian who built group into Arab world’s biggest drugmaker, joining blue-chip FTSE 100 index


Circassia deal signals UK biotech revival

Share placement shows fresh appetite for life-science drug groups

Endo Pharmaceuticals Pennsylvania headquarters

Endo/Par: too much of a good thing

The pharma group has rebuilt itself with deals but the latest is a big bite

Endo to buy Par in $8bn deal

TPG has roughly quintupled its $1.9bn investment

Big Pharma’s antibiotic resistance

Profit cannot be sole motive of an industry founded on making people better, writes Anjana Ahuja


Circassia lauds life-science investment

Invesco and Neil Woodford back anti-allergy specialist’s offering

23 Mar 2015 - Parsippany, New Jersey - Brent Saunders, Actavis CEO photographed in the New Jersey Office
©Sara Hylton

Brent Saunders, Actavis: Botox initiation

Dealmaking pharma CEO ‘ambushed’ into an extreme product test

Week in Review, May 16

Airbus crash inquiry; car recalls, Bombardier and cancer drugs also in the news

Drugs to watch in fight against cancer

Treatments turn the body’s immune system into a weapon

New drugs way to avoid an antibiotic apocalypse

Pharmaceutical industry needs incentives to overcome market failure

China’s vitamin market harder to crack

Producers such as Amway and Pfizer face increasing competition from locals such as By-Health

Big pharma risks backlash on antibiotics

Former Goldman Sachs economist warns industry will be criticised for not tackling drug resistance

US drug ‘super spenders’ cost $52bn

Report finds big rise in patients with bills of more than $50,000

Pharma M&A: Taking stock

When shares become a dealmaking currency, be careful

Copycat drugmakers pressured on prices

Teva’s $40bn pursuit of Mylan puts spotlight on generics sector

GSK chief questions pharma deal boom

Witty warns cheap money increasing risks of ‘poor choices’

GlaxoSmithKline: Out of step

In an interview, Andrew Witty, GSK’s embattled chief executive makes the case for his new strategy


Special report

insulin vials ©Jacob Ehrbahn Combating Diabetes

Special report

An elderly man uses a magnifier to see the descriptions on a pack of medicine at a pharmacy in Dandong, Liaoning province March 30, 2011 ©Jacky Chen/Reuter Health: Emerging Markets


More FT Twitter accounts